TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32405757
Drug: Nicotine (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (7 mg/24 h transdermally)
Study: 34192885
Drug: Tolperisone administered
Normalized name: tolperisone
DrugBank: Tolperisone (DB06264)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolperisone administered orally three-times daily for 14 days
Study: 33518129
Drug: In ovo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In ovo injection of organic microminerals (zinc, manganese, and copper)
Study: 34987600
Drug: Mild hypothermia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild hypothermia therapy
Study: 33459079
Drug: Self-managed computer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-managed computer therapy
Study: 34378260
Drug: 4% Pistacia
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% Pistacia atlantica ointment, applied topically three times a day for 8 weeks
Study: 34378260
Drug: Placebo ointment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment, applied topically three times a day for 8 weeks
Study: 32709430
Drug: Pranayama breathing
Normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pranayama breathing exercise group (PBE-G; n = 15)
Study: 32709430
Drug: Conventional breathing
Normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional breathing exercise group (CBE-G; n = 15)
Study: 32444038
Drug: Benson's Relaxation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benson's Relaxation Response (BRR) administered twice a day over 5 consecutive days
Study: 35606022
Drug: Regular, low-dose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular, low-dose, sustained-release morphine
Study: 36164102
Drug: Tafasitamab (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafasitamab (12 mg/kg IV on days 1, 8, 15, and 22 of a 28-day cycle for cycles 1-3, then days 1 and 15 for cycles 4-12) plus Lenalidomide (20 mg PO QD, days 1-21/cycle for 12 cycles) and Rituximab (375 mg/m2 IV on days 1, 8, 15, and 22 of cycle 1, then day 1 of cycles 2-5)
Study: 36164102
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% saline solution IV) plus Lenalidomide and Rituximab
Study: 33393645
Drug: BNP (B-type
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNP (B-type natriuretic peptide) via intravenous infusion, 2 µg/kg bolus followed by infusion at 0.01, 0.02, and 0.03 µg/kg/min for 1.5 hours
Study: 36113061
Drug: Ultrasound-guided peripheral
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided peripheral intravenous catheters (PIVC)
Study: 38912927
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) therapy
Study: 33049392
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate nasal spray (27.5 μg) 2 sprays once daily for 1 week, followed by as-needed use for 5 weeks (FF-as-needed)
Study: 33189909
Drug: Topical gelatin-thrombin
Normalized name: thrombin Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gelatin-thrombin matrix sealant (TGTMS)
Study: 34151818
Drug: Progressive Muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progressive Muscle Relaxation Therapy (PMRT)
Study: 34551211
Drug: 3D-CRT (Three-Dimensional
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3D-CRT (Three-Dimensional Conformal Radiation Therapy)
Study: 34310904
Drug: Androgen receptor
Normalized name: Androgen receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen receptor inhibitors (apalutamide, enzalutamide, or daralutamide)
Study: 32503517
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose yoga (LD), 60 min per week
Study: 32503517
Drug: Moderate dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate dose yoga (MD), 150 min per week
Study: 33044394
Drug: EMONO (1-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMONO (1-hour administration of equimolar mixture of oxygen and nitrous oxide)
Study: 35590386
Drug: Intravenous tenecteplase
Normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tenecteplase 0.25 mg/kg
Study: 32199541
Drug: Work Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Work Therapy (WT)
Study: 36156571
Drug: Modified Constraint-Induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Constraint-Induced Movement Therapy (MCIMT)
Study: 32088365
Drug: Positive Psychology
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive Psychology (PP) intervention, 8-session weekly phone-delivered group format
Study: 91213894
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g wheat bran (WB)
Study: 91213894
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g sugar-beet fiber (SBF)
Study: 34184295
Drug: Melatonin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (10 mg orally for 24 weeks)
Study: 34184295
Drug: Melatonin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (10 mg orally for 24 weeks) in nondiabetic patients
Study: 32576151
Drug: Lidocaine by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine by continuous intravenous administration
Study: 32151247
Drug: Sulfonylurea therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfonylurea therapy
Study: 32760144
Drug: Aussie-FIT intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aussie-FIT intervention (12 weekly 90-min sessions)
Study: 33354803
Drug: Placebo treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatments
Study: 35436823
Drug: Early initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Early initiation of low-dose hydrocortisone therapy
Study: 32166624
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment with pantoprazole (40 mg once daily)
Study: 33578661
Drug: Preventive outreach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive outreach educational intervention (oral health education in two one-hour sessions)
Study: 35247906
Drug: Famitinib, Camrelizumab,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famitinib, Camrelizumab, and Nab-paclitaxel combination
Study: 36213563
Drug: Oral implant
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral implant restoration
Study: 36091017
Drug: Renin-angiotensin system
Normalized name: Renin-angiotensin system inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renin-angiotensin system inhibitors (RASi) at maximum tolerant dose for 3 months
Study: 34168292
Drug: Contemporary matched
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Contemporary matched conventional therapy group (CTG)
Study: 33070144
Drug: Topical cidofovir
Normalized name: Cidofovir
DrugBank: Cidofovir (DB00369)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical cidofovir (first-line therapy)
Study: 33070144
Drug: Topical foscavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical foscavir (first-line therapy)
Study: 33070144
Drug: Intravenous foscavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous foscavir (first-line therapy)
Study: 33070144
Drug: Intravenous foscavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous foscavir (second-line therapy)
Study: 34704711
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL normal saline
Study: 34541941
Drug: Glucose-containing dialysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-containing dialysate (5.55 mmol/L)
Study: 35104042
Drug: Topical turmeric
Normalized name: Turmeric
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical turmeric cream
Study: 33342523
Drug: Treatment schools
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment schools with access to free breakfast, lunch, and supper on school days, and a food backpack on weekends and school breaks
Study: 35879482
Drug: Isocaloric/isonitrogenous control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocaloric/isonitrogenous control supplement
Study: 35656683
Drug: Honey solution
Normalized name: Honey
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Honey solution (5 mL)
Study: 35656683
Drug: Sterile water
Normalized name: sterile water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile water (5 mL)
Study: 36193978
Drug: High-dose dual
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dual therapy (HDDT) with esomeprazole 40 mg and amoxicillin 1000 mg three times daily for 14 days
Study: 36193978
Drug: Bismuth-containing quadruple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth-containing quadruple therapy (TFEB) with esomeprazole 40 mg, bismuth potassium citrate 220 mg, furazolidone 100 mg twice daily, and tetracycline 500 mg three times daily for 14 days
Study: 32713104
Drug: High-dose dual
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dual therapy (HDDT)
Study: 36193978
Drug: Bismuth-containing quadruple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth-containing quadruple therapy (TFEB)
Study: 35987013
Drug: Clonazepam (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam (0.5 mg twice daily)
Study: 36278336
Drug: Sling exercise
Normalized name: fu ling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sling exercise therapy (SET) for 4 weeks
Study: 33960674
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline irrigation twice daily using a 250-ml squeeze bottle in addition to standard treatment
Study: 32787541
Drug: Active outreach
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active outreach strategies (e.g., tabling in busy areas, attending community events, utilising mixed media, collaborating with clinic staff)
Study: 36105814
Drug: Half dose
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half dose of ChAdOx1 nCoV-19 vaccine
Study: 36105814
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose of ChAdOx1 nCoV-19 vaccine
Study: 34534317
Drug: Estradiol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol (100 µg/24 h) + Insulin (160 IU)
Study: 34534317
Drug: Insulin (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (160 IU)
Study: 32588034
Drug: High-speed power
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-speed power training (HSPT), 3 times weekly for 8 weeks
Study: 35710215
Drug: Passive Vertebral
Normalized name: Sus scrofa cerebral cortex preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive Vertebral Mobilization (PVM) + Routine Physical Therapy (RPT)
Study: 35710215
Drug: Routine Physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine Physical Therapy (RPT)
Study: 33078480
Drug: 30 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/day crocin for 12 weeks
Study: 36067791
Drug: Honglilai Vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Honglilai Vaginal Cream (0.625 mg/g) once daily for 3 weeks
Study: 34383975
Drug: Morphine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine treatment
Study: 36205036
Drug: Control (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (3 h of daily Uninterrupted Sitting)
Study: 33650444
Drug: Social interaction
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Social interaction with a therapy dog (no physical interaction)
Study: 33650444
Drug: Social plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social plus physical interaction with a therapy dog
Study: 33650444
Drug: No interaction
Approvals — FDA: no, EMA: no, PMDA: no
Description: No interaction with a therapy dog (control)
Study: 32463593
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate ODT (50 mg) without water
Study: 32755488
Drug: Optional prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optional prescription for oxycodone (group 2)
Study: 34488843
Drug: Qualitative risk
Normalized name: Hep B, adolescent/high risk infant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qualitative risk labels (e.g. 'very low risk')
Study: 33788454
Drug: Moxibustion therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxibustion therapy (20 minutes each session, once every other day for 8 weeks)
Study: 34491645
Drug: Acupuncture (at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (at Neiguan (PC 6), Hegu (LI 4), Yintang (GV 29), and Baihui (GV 20), twice a day until mechanical ventilation was offline)
Study: 34491645
Drug: Routine nursing
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine nursing and treatment of severe pneumonia (Control group)
Study: 37626303
Drug: Sugammadex (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex (2 mg/kg)
Study: 32910179
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human granulocyte colony-stimulating factor (rhG-CSF, 5 μg/kg, subcutaneously at days 0-2)
Study: 32027446
Drug: Oxycodone once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone once-daily (OOD) with 240 mL of 0% alcohol
Study: 32027446
Drug: Oxycodone once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone once-daily (OOD) with 240 mL of 40% alcohol
Study: 32027446
Drug: Oxycodone twice-daily
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxycodone twice-daily (OTD) with 240 mL of 40% alcohol
Study: 32027446
Drug: Oxycodone twice-daily
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxycodone twice-daily (OTD) with 240 mL of 0% alcohol
Study: 34037715
Drug: Ustekinumab (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab (both doses)
Study: 36791986
Drug: Bupivacaine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (40 mL of 0.25% bupivacaine)
Study: 36691187
Drug: Certain communication
Normalized name: cocklebur pollen extract
DrugBank: Xanthium strumarium pollen (DB10356)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Certain communication about COVID-19 vaccine effectiveness
Study: 36691187
Drug: Uncertain communication
Normalized name: cocklebur pollen extract
DrugBank: Xanthium strumarium pollen (DB10356)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uncertain communication about COVID-19 vaccine effectiveness
Study: 32894088
Drug: fluoxetine-placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: fluoxetine-placebo
Study: 32998416
Drug: Individualized Dietary
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized Dietary Prescription
Study: 32879998
Drug: Cysteamine 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cysteamine 5% cream
Study: 34214153
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation (10 or 30 μg daily)
Study: 32434376
Drug: Auricular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular therapy (Group A)
Study: 36169160
Drug: Clobetasol lotion
Normalized name: clobetasol Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobetasol lotion 0.05% once at night
Study: 33370050
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of ibuprofen (NSAID)
Study: 33370050
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg hydrocodone with 325 mg acetaminophen (opioid)
Study: 33905350
Drug: Multidimensional family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidimensional family therapy (MDFT)
Study: 32059704
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with Gemcitabine + Cisplatin (3 cycles pre- and post-surgery)
Study: 32059704
Drug: Surgery alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery alone followed by therapy of investigator's choice
Study: 35056349
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (electroacupuncture at left PC5, PC6, ST36, and ST37, once weekly for 12 weeks)
Study: 35413570
Drug: Zinc gluconate
Normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc gluconate (30 mg/day)
Study: 36498457
Drug: Ramosetron (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramosetron (5 μg; n = 35)
Study: 32008289
Drug: Neostigmine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (2 mg) combined with atropine (0.5-1.0 mg)
Study: 36167891
Drug: Daily multiple
Normalized name: Daily Multiple Vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily multiple micronutrient powder (MNP)
Study: 36167891
Drug: Daily preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily preventive zinc tablets (PZ)
Study: 34101714
Drug: Dexmedetomidine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine infusion (0.5 μg kg‐1 h‐1) combined with GDHT
Study: 32340838
Drug: Extracorporeal Shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal Shock Wave Therapy and Dry Needling (ESWT-DN)
Study: 34318597
Drug: Inhaled nezulcitinib
Normalized name: NEZULCITINIB
DrugBank: TD-0903 (DB16463)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nezulcitinib (10 mg)
Study: 34318597
Drug: Inhaled nezulcitinib
Normalized name: NEZULCITINIB
DrugBank: TD-0903 (DB16463)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nezulcitinib (1, 3, or 10 mg)
Study: 32546278
Drug: PGE2 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PGE2 treatment
Study: 34422085
Drug: Extracorporeal Shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal Shock Wave Therapy (ESWT), two times/week for 4 weeks
Study: 33272279
Drug: mHealth solution
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: mHealth solution using the 24alife app with a compliance rate of 94.1%
Study: 33272279
Drug: mHealth solution
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: mHealth solution using the 24alife app
Study: 36431167
Drug: Topical intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical intervention (SuperCalm)
Study: 36431167
Drug: Oral intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral intervention (InnerCalm)
Study: 32024950
Drug: Daratumumab 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daratumumab 16 mg/kg intravenously on intense dosing schedule
Study: 32024950
Drug: Daratumumab 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daratumumab 16 mg/kg intravenously on intermediate dosing schedule
Study: 32024950
Drug: Daratumumab 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daratumumab 16 mg/kg intravenously on short dosing schedule
Study: 33257632
Drug: FDC treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC treatment in Shandong Province for six months
Study: 33257632
Drug: FDC treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC treatment in Jilin Province for six months
Study: 36474739
Drug: Dorsal penile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorsal penile nerve block (DPNB) alone with 4 mg/kg plain lidocaine
Study: 36474739
Drug: Lidocaine-prilocaine cream
Normalized name: lidocaine / prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine-prilocaine cream (LPC) applied to the phallus 1 hour before DPNB
Study: 34016612
Drug: Cotadutide 100
Normalized name: Cotadutide
DrugBank: Cotadutide (DB15194)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotadutide 100 μg
Study: 34016612
Drug: Cotadutide 200
Normalized name: Cotadutide
DrugBank: Cotadutide (DB15194)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotadutide 200 μg
Study: 38729399
Drug: Cotadutide 300
Normalized name: Cotadutide
DrugBank: Cotadutide (DB15194)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotadutide 300 μg
Study: 34740705
Drug: EDP-305 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDP-305 2.5 mg
Study: 32827416
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no orthodontic treatment)
Study: 33823377
Drug: Homeopathic dose
Normalized name: Urtica urens homeopathic preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic dose of pyridoxine (placebo, 59 of 105, 56%)
Study: 32476164
Drug: Group intervention
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group intervention (n = 40); eight weekly 1.5-hour sessions
Study: 32476164
Drug: Guided self-help
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Guided self-help (GSH) intervention (n = 31); self-study with eight weekly 20-minute phone calls
Study: 33675398
Drug: Splint +
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Splint + exercise therapy
Study: 35533490
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no cold therapy)
Study: 34620621
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg ertugliflozin
Study: 34620621
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg ertugliflozin
Study: 33849723
Drug: Typbar-TCV® (WHO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typbar-TCV® (WHO prequalified vaccine)